A new study shows that the Shingles vaccine may offer more than just protection from painful rashes—it could also reduce the risk of dementia. Researchers at Stanford University have found a potential link between the vaccine and a 20% decrease in dementia diagnoses, based on a detailed analysis of UK health data.
Shingles Vaccine Shows Promise in Dementia Prevention
Published in Nature, the study examined individuals in Wales, UK, where eligibility for the Shingles vaccine was determined solely by birthdate. Those born just after September 2, 1933, were eligible, while those born just before were not. This rare policy feature created a natural experiment that allowed researchers to compare similar individuals with and without vaccine access.
Over a seven-year follow-up, researchers observed a 3.5 percentage point reduction in dementia diagnoses among eligible individuals, translating to a 20% relative risk reduction.
Stronger Impact Observed in Women
The effect of the Shingles vaccine was notably stronger in women, where statistical significance was reached. In men, results were less definitive due to wider confidence intervals. Interestingly, the reduction in dementia risk became evident more than a year after vaccination, suggesting longer-term immune-related changes might be at play.
Possible Immune Benefits of Shingles Vaccination
While the Shingles vaccine is primarily used to prevent the varicella-zoster virus from reactivating, it may also reduce neuroinflammation—one of the factors linked to dementia. Scientists suggest that live-attenuated vaccines like the one used in this study might boost immune responses in a way that offers indirect brain protection.
Study Based on Zostavax, Not Shingrix
The findings are specific to the live-attenuated Shingles vaccine, Zostavax. The recombinant vaccine Shingrix, now more commonly used, was not included in this study. Future research is needed to determine if it provides similar cognitive benefits.
Shingles Vaccine Could Be a Cost-Effective Preventive Tool
With dementia continuing to rise globally and no definitive cure, this study points to this vaccine as a potential low-risk, cost-effective method for prevention. Already widely available for preventing Shingles, this vaccine may also hold unexpected promise in supporting cognitive health.
For more information: Eyting, M., Xie, M., Michalik, F. et al. (2025). A natural experiment on the effect of herpes zoster vaccination on dementia. Nature. DOI:10.1038/s41586-025-08800-x https://www.nature.com/articles/s41586-025-08800-x
more recommended stories
Red Blood Cells Improve Glucose Tolerance Under HypoxiaKey Takeaways for Clinicians Chronic hypoxia.
Nanoplastics in Brain Tissue and Neurological RiskKey Takeaways for HCPs Nanoplastics are.
AI Predicts Chronic GVHD Risk After Stem Cell TransplantKey Takeaways A new AI-driven tool,.
Red Meat Consumption Linked to Higher Diabetes OddsKey Takeaways Higher intake of total,.
Pediatric Crohn’s Disease Microbial Signature IdentifiedKey Points at a Glance NYU.
Nanovaccine Design Boosts Immune Attack on HPV TumorsKey Highlights Reconfiguring peptide orientation significantly.
High-Fat Diets Cause Damage to Metabolic HealthKey Points Takeaways High-fat and ketogenic.
Acute Ischemic Stroke: New Evidence for NeuroprotectionKey Highlights A Phase III clinical.
Statins Rarely Cause Side Effects, Large Trials ShowKey Points at a Glance Large.
Anxiety Reduction and Emotional Support on Social MediaKey Summary Anxiety commonly begins in.
Leave a Comment